CL2020002598A1 - Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida - Google Patents
Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituidaInfo
- Publication number
- CL2020002598A1 CL2020002598A1 CL2020002598A CL2020002598A CL2020002598A1 CL 2020002598 A1 CL2020002598 A1 CL 2020002598A1 CL 2020002598 A CL2020002598 A CL 2020002598A CL 2020002598 A CL2020002598 A CL 2020002598A CL 2020002598 A1 CL2020002598 A1 CL 2020002598A1
- Authority
- CL
- Chile
- Prior art keywords
- preparation
- triazolone
- trisubstituted
- compound
- intermediates
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- -1 2,4,5-trisubstituted 1,2,4-triazolone Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención proporciona métodos para la preparación del Compuesto (I), el uso de compuestos intermedios para la preparación de dicho compuesto y su forma cristalina A.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18166552 | 2018-04-10 | ||
| EP18212916 | 2018-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002598A1 true CL2020002598A1 (es) | 2020-12-04 |
Family
ID=66001239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002598A CL2020002598A1 (es) | 2018-04-10 | 2020-10-08 | Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11365179B2 (es) |
| EP (1) | EP3774786B1 (es) |
| JP (1) | JP7476107B2 (es) |
| KR (1) | KR20200141066A (es) |
| CN (1) | CN112236426B (es) |
| AU (1) | AU2019251694A1 (es) |
| BR (1) | BR112020020596A2 (es) |
| CA (1) | CA3096477A1 (es) |
| CL (1) | CL2020002598A1 (es) |
| CO (1) | CO2020012574A2 (es) |
| IL (1) | IL277860A (es) |
| JO (1) | JOP20200256A1 (es) |
| MX (1) | MX2020010655A (es) |
| PE (1) | PE20210159A1 (es) |
| SG (1) | SG11202009943QA (es) |
| TW (1) | TW201945346A (es) |
| WO (1) | WO2019197239A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190094A1 (ar) | 2016-10-27 | 2019-04-25 | Broad Inst Inc | مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh) |
| US10968216B2 (en) * | 2016-10-27 | 2021-04-06 | Bayer Aktiengesellschaft | 4,5-annulated 1,2,4-triazolones |
| CN116804004A (zh) * | 2020-07-14 | 2023-09-26 | 南京征祥医药有限公司 | 作为dhodh抑制剂的化合物 |
| CN111773214B (zh) * | 2020-07-17 | 2021-04-20 | 中国人民解放军军事科学院军事医学研究院 | 2,4,5-三取代的1,2,4-三唑酮在制备抗病毒药物中的用途 |
| CN116444525B (zh) * | 2023-03-27 | 2024-11-12 | 四川青木制药有限公司 | 一种盐酸泊那替尼a晶型的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2156472A1 (de) | 1970-11-23 | 1972-05-31 | Ciba-Geigy Ag, Basel (Schweiz) | Verfahren zur Herstellung von neuen Diazepinderivaten |
| US4089958A (en) | 1976-12-20 | 1978-05-16 | American Home Products Corporation | 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2]quinoxalin-5(6)-ones and derivatives thereof |
| EP0586513A1 (en) * | 1991-05-10 | 1994-03-16 | Merck & Co. Inc. | Acidic aralkyl triazole derivatives active as angiotensin ii antagonists |
| DE19627901A1 (de) | 1996-07-11 | 1998-01-15 | Bayer Ag | Substituierte aromatische Carbonylverbindungen und ihre Derivate |
| DE19816882A1 (de) | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Triazolone mit neuroprotektiver Wirkung |
| AR022889A1 (es) | 1999-03-12 | 2002-09-04 | Bayer Cropscience Ag | Agente desfoliante |
| KR20100124262A (ko) * | 2008-02-13 | 2010-11-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 비시클로아민 유도체 |
| EP2373645A4 (en) | 2008-12-08 | 2012-05-02 | Sirtris Pharmaceuticals Inc | ISOINDOLINONE AND RELATED ANALOGUES AS SIRTUIN MODULATORS |
| JP5868575B2 (ja) | 2010-04-15 | 2016-02-24 | 浜松ホトニクス株式会社 | 接続基板 |
| CN103006645A (zh) * | 2011-09-27 | 2013-04-03 | 华东理工大学 | 2-氨基苯并噻唑衍生物作为dhodh抑制剂的应用 |
| TWI568722B (zh) * | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
| MX355439B (es) | 2012-12-05 | 2018-04-18 | Merck Sharp & Dohme | Proceso para preparar inhibidores de la transcriptasa inversa. |
| US20160251341A1 (en) | 2015-02-27 | 2016-09-01 | Verseon Corporation | Substituted triazole compounds as serine protease inhibitors |
| JOP20190094A1 (ar) | 2016-10-27 | 2019-04-25 | Broad Inst Inc | مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh) |
| US10968216B2 (en) | 2016-10-27 | 2021-04-06 | Bayer Aktiengesellschaft | 4,5-annulated 1,2,4-triazolones |
-
2019
- 2019-04-01 TW TW108111523A patent/TW201945346A/zh unknown
- 2019-04-03 KR KR1020207031949A patent/KR20200141066A/ko not_active Withdrawn
- 2019-04-03 JP JP2020555437A patent/JP7476107B2/ja active Active
- 2019-04-03 AU AU2019251694A patent/AU2019251694A1/en not_active Abandoned
- 2019-04-03 CA CA3096477A patent/CA3096477A1/en active Pending
- 2019-04-03 JO JOP/2020/0256A patent/JOP20200256A1/ar unknown
- 2019-04-03 CN CN201980037684.3A patent/CN112236426B/zh active Active
- 2019-04-03 MX MX2020010655A patent/MX2020010655A/es unknown
- 2019-04-03 PE PE2020001572A patent/PE20210159A1/es unknown
- 2019-04-03 WO PCT/EP2019/058389 patent/WO2019197239A1/en not_active Ceased
- 2019-04-03 EP EP19715094.9A patent/EP3774786B1/en active Active
- 2019-04-03 BR BR112020020596-6A patent/BR112020020596A2/pt not_active Application Discontinuation
- 2019-04-03 SG SG11202009943QA patent/SG11202009943QA/en unknown
- 2019-04-03 US US17/046,143 patent/US11365179B2/en active Active
-
2020
- 2020-10-07 IL IL277860A patent/IL277860A/en unknown
- 2020-10-08 CO CONC2020/0012574A patent/CO2020012574A2/es unknown
- 2020-10-08 CL CL2020002598A patent/CL2020002598A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL277860A (en) | 2020-11-30 |
| JOP20200256A1 (ar) | 2020-10-08 |
| MX2020010655A (es) | 2020-10-28 |
| PE20210159A1 (es) | 2021-01-26 |
| CO2020012574A2 (es) | 2020-10-30 |
| US20210032212A1 (en) | 2021-02-04 |
| US11365179B2 (en) | 2022-06-21 |
| WO2019197239A1 (en) | 2019-10-17 |
| EP3774786A1 (en) | 2021-02-17 |
| CN112236426A (zh) | 2021-01-15 |
| EP3774786B1 (en) | 2024-12-25 |
| AU2019251694A1 (en) | 2020-10-22 |
| JP7476107B2 (ja) | 2024-04-30 |
| SG11202009943QA (en) | 2020-11-27 |
| CA3096477A1 (en) | 2019-10-17 |
| CN112236426B (zh) | 2024-07-05 |
| KR20200141066A (ko) | 2020-12-17 |
| JP2021521166A (ja) | 2021-08-26 |
| BR112020020596A2 (pt) | 2021-01-12 |
| TW201945346A (zh) | 2019-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002598A1 (es) | Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida | |
| CO2022002637A2 (es) | Proceso de fabricación de moduladores de cftr | |
| CL2019002792A1 (es) | Composición para producir tagatosa y procedimiento de producción de tagatosa usando el mismo. | |
| MX2018016331A (es) | Formas cristalinas de compuesto de triazolopirimidina. | |
| UY36730A (es) | Fenoxifenilamidinas sustituidas con halógeno y el uso de estas como fungicidas | |
| MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
| MX382261B (es) | Derivados heterociclicos y uso de los mismos. | |
| AR095039A1 (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
| MX384201B (es) | Proceso para la preparacion de treprostinil. | |
| AR111304A1 (es) | Métodos para sintetizar un inhibidor de mcl-1 | |
| AR112276A1 (es) | Polimorfos de 5-fluoro-4-imino-3-metil-1-tosil-3,4-dihidropirimidin-2-ona | |
| UY36781A (es) | Fenoxihalogenofenilamidinas y su uso como fungicidas | |
| BR112019023123A2 (pt) | Artigo pultrudado, uso do artigo pultrudado, método para formar o artigo | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| DK3582780T3 (da) | Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer | |
| AR110768A1 (es) | Formas cristalinas de tenofovir alafenamida | |
| LT3805220T (lt) | Policikliniai karbamoilpiridono dariniai, skirti živ gydymui | |
| CO2020007895A2 (es) | Inhibidores de histona acetiltransferasa de la familia myst | |
| CL2019001804A1 (es) | Activador de nrf2. | |
| UY40794A (es) | Formas cristalinas de (s)-afoxolaner | |
| PT3908584T (pt) | Formas cristalinas de 1-(1,2-dimetilpropil)-n-etil-5- metil-n-piridazin-4-il-pirazol-4-carboxamida | |
| CO2020006206A2 (es) | Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción | |
| CL2020000217A1 (es) | Inhibidores de ror gamma. | |
| CL2021001922A1 (es) | Procedimientos para tratamiento de enfermedades con inhibidores de magl. | |
| CL2017000151A1 (es) | Derivados de piridona |